Europe 1 with AFP 8:33 p.m., March 10, 2023
A treatment against migraine, developed by the Pfizer laboratory, has just been approved by the American health authorities.
This drug has the particularity of being administered by nasal aerosol, and represents an alternative for those who are unable to ingest drugs.
US health authorities have authorized a new anti-migraine treatment which has the particularity of being administered by a nasal aerosol, the pharmaceutical giant Pfizer announced on Friday.
The treatment, which will be marketed by the American laboratory under the name of Zavzpret, has been authorized for the treatment of severe migraines in adults.
In a large clinical trial, the results of which were published last month in the scientific journal Lancet Neurology, the drug demonstrated positive pain-relieving effects over a placebo, sometimes as quickly as 15 minutes after a dose. , pointed out Pfizer.
>> READ ALSO -
Pfizer plans to sell 54 billion USD of anti-Covid vaccines and pills in 2022
The treatment available from July in the United States
"One of the most important characteristics of an acute treatment option is how quickly it works," said Kathleen Mullin of the New England Institute for Neurology & Headache, quoted in the Pfizer statement.
“As a nasal spray with rapid absorption, Zavzpret offers an alternative treatment option for those in need of relief who cannot take oral medications, due to nausea or vomiting,” she said. added.
Migraines can have a significant effect on daily life, and are often accompanied, in addition to headaches, by visual disturbances or an intolerance to light.
Pfizer said the treatment would be available in US pharmacies in July 2023. The molecule used is called zavegepant.
The American giant bought Biohaven a year ago for more than ten billion dollars, the company that develops zavegepant and other migraine treatments.